Korea United Pharm. Inc.

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Activity

Recent Activity

Last 14 days

Jul 9, 2026

Completed

Phase 1 Study to Evaluate the Safety and the Pharmacokinetics of "UI111" and "UIC202006" in Healthy Adult Volunteers Under Fed State Conditions

Jul 7, 2026

Recruiting

A Randomized, Open-label, Two-arm, Two-period, Multiple-dose, Study to Evaluate Pharmacokinetic Drug-drug Interaction, Safety and Tolerability of UIC202601 and UIC202602 in Healthy Volunteers

Earlier

Aug 12, 2025TrialA Two-arm, Open-label, Single-sequence, Multiple-dose, Cross-over Study to Evaluate the Pharmacokinetic Interaction and the Safety of UIC202502 and UIC202505 in Healthy Adult Volunteers

Oct 24, 2024TrialBioequivalence Study Between UI009 and UIC202005 in Healthy Subjects

Jul 3, 2024TrialA Study to Compare and Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of UI059 and UIC202201

Oct 8, 2023TrialA Study to Compare Pharmacokinetics, Pharmacodynamics and Safety of UI059 and UIC202201 in Healthy Subjects

Mar 11, 2023TrialA Clinical Study to Evaluate the Safety and the Pharmacokinetics of UI068 in Healthy Adult Volunteers Under Fed Conditions

Nov 1, 2021TrialArformoterol/Budesonide for COVID-19

3 more events

Sep 6, 2021TrialStudy to Evaluate the Safety and PK of UI018

Feb 3, 2021TrialA Study to Compare PK, PD and Safety of UI058 and UIC202004 in Healthy Subjects

Mar 15, 2017TrialDrug-drug Interaction Study Between UIC201603, and UIC201604

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)